DelveInsight’s ‘LAG-3-Next Generation Immunotherapy—Competitive Landscape and Market Forecast–2035’ report delivers an in-depth understanding of the LAG-3 as well as the market trends of LAG-3-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The report provides the upcoming drugs, market share of this target by indications, forecasted market size of LAG-3-Next Generation Immunotherapy from 2022 to 2035 segmented by seven major markets. This report discusses the recent findings on LAG-3, the role it plays in regulating immune responses in different cell types and the rationale for targeting LAG-3 for effective cancer immunotherapy. The report also covers the current scenario, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2022–2035
View report: https://www.delveinsight.com/report-store/lag-3-next-generation-immunotherapy-competitive-landscape
LAG-3-Next Generation Immunotherapy Understanding
Cancer immunotherapy (CI) is rapidly advancing and can now be considered to be the “fifth pillar” of cancer therapy, joining the ranks of surgery, cytotoxic chemotherapy, radiation, and targeted therapy. The CI which has sparked the most interest involves antibodies to inhibitory immune checkpoint molecules. Fighting cancer with immunotherapy has revolutionized treatment for some patients and therapies targeting the immune checkpoint molecules such as CTLA-4 and PD-1 have achieved durable responses in melanoma, renal cancer, Hodgkin’s diseases and lung cancer. However, the success rate of these treatments has been low and a large number of cancers, including colorectal cancer remain largely refractory to CTLA-4 and PD-1 blockade.
Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor protein found on the cell surface of effector T cells and regulatory T cells (Tregs) and functions to control T cell response, activation, and growth. T cells are a type of white blood cell that are part of the immune system. Activation of cytotoxic T cells by antigens enables them to kill unhealthy or foreign cells. It binds MHCII molecules and modulates T-cell function than either CTLA-4 or PD-1. It acts by regulating CD8+ Tcell expansion in immune reactions that have already been initiated (inhibitory signal) and also, by increasing the Treg cell activity.
LAG-3-Next Generation Immunotherapy Drug Chapters
This segment of the LAG-3-Next Generation Immunotherapy report encloses the detailed analysis of late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the indication-specific clinical trial details, expressive pharmacological actions, agreements and collaborations, approval and awards, advantages and disadvantages of each included drug, and the latest news and press releases.
The major key players such as MacroGenics/Zai Lab, Bristol-Myers Squibb/Ono Pharmaceuticals, Immutep, Novartis, Merck, F-star Therapeutics, Regeneron, Xencor, Incyte Biosciences/Agenus, Roche, GlaxoSmithKline, Innovent Biologics (Suzhou) Co. Ltd. and others will significantly increase the market during the forecast period (2022–2035).
Request for sample pages: https://www.delveinsight.com/sample-request/lag-3-next-generation-immunotherapy-competitive-landscape
Scope of the report
• The report covers the descriptive overview of LAG-3-Next Generation Immunotherapy, explaining its pathophysiology, and current trends in the research.
• Additionally, an all-inclusive account of emerging therapies for LAG-3-Next Generation Immunotherapy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of LAG-3-Next Generation Immunotherapy market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the LAG-3-Next Generation Immunotherapy market.
Table of contents:
1. Key Insights
2. Executive Summary
3. Competitive Intensity of LAG-3-Next Generation Immunotherapy
4. Market Competition of LAG-3-Next Generation Immunotherapy
5. Technological innovations in LAG-3-Next Generation Immunotherapy
6. Multivariate analysis of the key players in LAG-3-Next Generation Immunotherapy
7. LAG-3-Next Generation Immunotherapy Market Overview at a Glance
7.1. Market Share (%) Distribution of Next-Generation Immunotherapy in 2035
8. Pipeline Therapeutics Analysis (Active Products)
9. Overview: Next Generation Immunotherapy
9.1. Immune Checkpoint Inhibitors
9.2. LAG-3
10. Future Prospects and Challenges in LAG-3-Next Generation Immunotherapy
10.1. Current Clinical Challenges in Immunotherapies
10.2. Future direction of improving response rates of Immunotherapy
11. SWOT Analysis
12. Epidemiology and Forecasting Assumptions
13. Emerging Drugs
13.1. Target indications of LAG-3
13.2. MGD013: MacroGenics/Zai Lab
13.2.1. Drug Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Development
13.2.4. Product Profile
13.3. MBG453: Novartis
13.3.1. Product Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.3.4. Product Profile
13.4. Relatlimab: Bristol-Myers Squibb/Ono Pharmaceuticals
13.4.1. Product Description
13.4.2. Other Developmental Activities
13.4.3. Clinical Development
13.4.4. Product Profile
13.5. Eftilagimod Alpha (IMP321): Immutep
13.5.1. Drug Description
13.5.2. Clinical Development
13.5.3. Product Profile
13.6. LAG525: Novartis
13.6.1. Product Description
13.6.2. Other Developmental Activities
13.6.3. Clinical Development
13.6.4. Product Profile
13.7. MK-4280: Merck
13.7.1. Product Description
13.7.2. Other Developmental Activities
13.7.3. Clinical Development
13.7.4. Product Profile
13.8. REGN3767: Regeneron
13.8.1. Product Description
13.8.2. Other Developmental Activities
13.8.3. Clinical Development
13.8.4. Product Profile
13.9. FS118: F-star Therapeutics
13.9.1. Product Description
13.9.2. Other Developmental Activities
13.9.3. Clinical Development
13.9.4. Product Profile
13.10. XmAb22841: Xencor
13.10.1. Product Description
13.10.2. Other Developmental Activities
13.10.3. Clinical Development
13.10.4. Product Profile
13.11. INCAGN2385: Incyte Biosciences/Agenus
13.11.1. Product Description
13.11.2. Other Developmental Activities
13.11.3. Clinical Development
13.11.4. Product Profile
13.12. RO7247669: Roche
13.12.1. Product Description
13.12.2. Other Developmental Activities
13.12.3. Clinical Development
13.12.4. Product Profile
13.13. TSR-033: GlaxoSmithKline
13.13.1. Product Description
13.13.2. Other Developmental Activities
13.13.3. Clinical Development
13.13.4. Product Profile
13.14. IBI110: Innovent Biologics (Suzhou) Co. Ltd.
13.14.1. Product Description
13.14.2. Other Developmental Activities
13.14.3. Clinical Development
13.14.4. Product Profile
14. Assessment by Indication
15. Assessment by Route of Administration
16. Assessment by Stage and Indication
17. Assessment by stage and Route of Administration
18. LAG-3-7 Major Market Analysis
18.1. Market Outlook in the 7MM
18.1.1. Total Market size of LAG-3 in 7MM
18.1.2. Market Size of LAG-3 by indication in 7MM
19. Market Drivers
20. Market Barriers
21. Appendix
21.1. Report Methodology
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
Download report: https://www.delveinsight.com/sample-request/lag-3-next-generation-immunotherapy-competitive-landscape
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/